EUVIMEDScopri EUVIMED
Crossref

Design, Synthesis and Biological Evaluation of Histone Deacetylase Inhibitors Based on Pyrrolo[2,3‐ d ]pyrimidine and Pyrrolo[2,3‐ b ]pyridine Scaffolds

Nian-Dong Mao, Yuan Gao, Xia-Wen Dang, Ji-Long Duan, Zi Hui, Hao Che, Yueying Xu, Hang Zhang, Xingrui He iD, Carmen Garrido, Xiang-Yang Ye iD

ChemMedChem · 2023

DOI: 10.1002/cmdc.202200683 ↗

At a glance

Journal article in ChemMedChem, 2023. Written by Nian-Dong Mao and 10 co-authors. Institution: School of Pharmacy, Hangzhou Normal University, Hangzhou, China. Major MEDLINE topics: Histone Deacetylase Inhibitors, Antineoplastic Agents. Cited 6 times so far (Crossref); 44 references. Funded by: National Natural Science Foundation of China, Science and Technology Department of Zhejiang Province.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Histone deacetylases (HDACs) are validated targets for the development of anticancer drugs in epigenetics. We have designed and synthesized a series of novel HDAC inhibitors based on pyrrolo[2,3‐ d ]pyrimidine and pyrrolo[2,3‐ b ]pyridine scaffolds. Compound B3 {( E )‐3‐(4‐(((1‐(7 H ‐pyrrolo[2,3‐ d ]pyrimidin‐4‐yl)piperidin‐4‐yl)amino)methyl)phenyl)‐ N ‐hydroxyacrylamide} exhibits potent inhibitory activity against HDACs 1, 2, 3, 6, and 8 with IC 50 values of 5.2, 6.0, 8.8, 4.4, and 173.0 nM, respectively. It exhibited potent antiproliferative effects against three tumour cell lines (IC 50 values of 0.13, 0.37, and 1.11 μM, against MV‐4‐11, K562, and WSU‐DLCL‐2 cells, respectively) with two‐ to sixfold improvement relative to suberoylanilide hydroxamic acid (SAHA). Mechanistic studies on WSU‐DLCL‐2 cells revealed that B3 exhibits anticancer effects through the induction of G 0 /G 1 ‐phase arrest and promotion of apoptosis. The results of this study warrant further investigation of this compound series for the treatment of hematological malignancy.

Subjects

MeSH terms (MEDLINE)

Histone Deacetylase InhibitorsAntineoplastic AgentsStructure-Activity RelationshipDrug Screening Assays, AntitumorDrug DesignCell Line, TumorPyrimidinesPyridinesCell ProliferationHydroxamic Acids

Author keywords

anticancer agentsdrug designhematological malignancyhistone deacetylaseinhibitors

Substances

Histone Deacetylase InhibitorsAntineoplastic AgentsPyrimidinesPyridinesHydroxamic Acids

Authors and institutions

  • School of Pharmacy, Hangzhou Normal University, Hangzhou, China.
  • Key Laboratory of Elemene Class Anti-Cancer Chinese Medicine of Zhejiang Province, Hangzhou, China.
  • Engineering Laboratory of Development and Application of Traditional Chinese Medicine from Zhejiang Province, Hangzhou, China.
  • t/>Collaborative Innovation Center of Chinese Medicines from, Zhejiang Province, Hangzhou, China.
  • Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
  • School of Basic Medical Science, Hangzhou Normal University, Hangzhou, China.

ORCID profiles: Xingrui He, Xiang-Yang Ye

Funding

  • National Natural Science Foundation of China
  • Science and Technology Department of Zhejiang Province

Cite

APA

Mao, N. D., Gao, Y., Dang, X. W., Duan, J. L., Hui, Z., Che, H., Xu, Y., Zhang, H., He, X., Garrido, C., & Ye, X. Y. (2023). Design, Synthesis and Biological Evaluation of Histone Deacetylase Inhibitors Based on Pyrrolo[2,3‐ d ]pyrimidine and Pyrrolo[2,3‐ b ]pyridine Scaffolds. ChemMedChem. https://doi.org/10.1002/cmdc.202200683

Vancouver

Mao ND, Gao Y, Dang XW, Duan JL, Hui Z, Che H, et al. Design, Synthesis and Biological Evaluation of Histone Deacetylase Inhibitors Based on Pyrrolo[2,3‐ d ]pyrimidine and Pyrrolo[2,3‐ b ]pyridine Scaffolds. ChemMedChem. 2023. doi:10.1002/cmdc.202200683

BibTeX
@article{Mao2023,
  author = {Mao, Nian-Dong and Gao, Yuan and Dang, Xia-Wen and Duan, Ji-Long and Hui, Zi and Che, Hao and Xu, Yueying and Zhang, Hang and He, Xingrui and Garrido, Carmen and Ye, Xiang-Yang},
  title = {Design, Synthesis and Biological Evaluation of Histone Deacetylase Inhibitors Based on Pyrrolo[2,3‐ d ]pyrimidine and Pyrrolo[2,3‐ b ]pyridine Scaffolds},
  journal = {ChemMedChem},
  year = {2023},
  doi = {10.1002/cmdc.202200683}
}
Start for free →